{"slug":"foxo4-dri","seoKey":"foxo4dri","displayName":"FOXO4-DRI","codes":[],"synonyms":["FOXO4 D-retro-inverso peptide","FOXO4-DRI peptide","proxofim (trade designation, not a scientific or regulatory name)","FOX04-DRI (common misspelling with a zero)"],"legalClass":"research_chemical","identifiers":{"cas":"2460055-10-9","pubchemCid":167312269,"inchikey":"WVZCDZFJLXBWHG-XXZPGMBKSA-N","wikidataQid":"Q136955527","formula":"C228H388N86O64","molecularWeight":5358,"sequence":"ltlrkepaseiaqsileaysqngwanrrsggkrppprrrqrrkkrg"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved and not the subject of any compounding procedure. A full-text search of the May 2026 advisory committee briefing document returned no mention of the substance on 2026-09-06.","source":"https://www.fda.gov/media/193342/download"},{"market":"EU","status":"not_approved","note":"No centralised marketing authorisation, no assessment report and no orphan designation. No entry found on 2026-09-06.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=FOXO4"},{"market":"DE","status":"not_approved","note":"No national or EU marketing authorisation; no finished medicinal product may be placed on the market. The customary label as research material does not change that classification. No entry found on 2026-09-06.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=FOXO4"},{"market":"UK","status":"not_approved","note":"No marketing authorisation and no registered clinical trial. No entry found on 2026-09-06.","source":"https://products.mhra.gov.uk/search/?search=FOXO4"},{"market":"AU","status":"not_approved","note":"Not registered in the Australian Register of Therapeutic Goods and not named in the Poisons Standard; a full-text search on 2026-09-06 returned no entry. Unapproved therapeutic goods remain regulated regardless.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"No marketing authorisation and no entry in the drug product database. No entry found on 2026-09-06.","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=FOXO4"},{"market":"CH","status":"not_approved","note":"No marketing authorisation. No entry found in the Swiss medicinal product information on 2026-09-06.","source":"https://www.swissmedicinfo.ch/"}],"devStage":"preclinical","strongestEvidence":"animal","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://www.wikidata.org/wiki/Q136955527","https://pubchem.ncbi.nlm.nih.gov/compound/167312269"],"lastVerified":"2026-09-06","version":"1.0","published":true,"locale":"en","title":"FOXO4-DRI: what the studies show, status and safety","summary":"FOXO4-DRI is a lab-made peptide designed to kill senescent cells, meaning cells that have stopped dividing but do not clear themselves away. Everything known about it comes from cells in dishes, from isolated tissue and from rodents, and above all from a single paper published in 2017. No study in people has ever been registered or published, and nobody has tested whether the peptide extends life in any species. A 2023 study found that clearing these cells in this way made blood flow through the lungs of mice worse.","updated":"2026-09-06","url":"https://mypep.app/peptides/foxo4-dri"}